Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rose 14.6% over 21 sessions and closed at the assessment-period high. Q2 VYJUVEK revenue reached $119.2 million, while 94.6% gross margin, strong profitability, international launches, and second-half 2026 clinical readouts support continuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High Profitability ⢠Strong Liquidity ⢠Low Leverage KRYS combines exceptional profitability, liquidity, and low leverage with strong cash generation, but its premium valuation, margin compression, and dilution risk warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Positive monthly trend ⢠Weakening near-term momentum ⢠Key breakout pivot Support Level: $341.72 Resistance Level: $358â$360 KRYS is up ~6% over the last month but short-term momentum is weakening; reclaiming $358â$360 would turn bullish, while a break below $341.72 would signal downside risk.
Sentiment & News
Key News Insights: ⢠Stock Momentum ⢠Pipeline Growth ⢠Institutional Interest Krystal Biotech's strong stock gains, Vyjuvek growth, pipeline progress, and new HSBC ownership signal favorable investor momentum.
AI Summary
KRYS is now a cash-rich, highly profitable VYJUVEK commercial story rather than a financing-dependent gene-therapy bet, but its premium valuation requires successful European reimbursement/pricing execution and credible pipeline data to offset maturing U.S. growth; investors should favor sustained upside only if these next-stage catalysts validate a durable multi-product trajectory.
Description
Krystal Biotech is a clinical-stage biotechnology company developing redosable gene therapies for serious, primarily rare, dermatologic and genetic conditions. Its lead candidate, beremagene geperpavec (B-VEC), is in Phase III for dystrophic epidermolysis bullosa, while a portfolio of other programs spans early- and preclinical development for congenital ichthyosis, netherton syndrome, cystic fibrosis and multiple dermatology indications including aesthetic applications. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | KRYS | Krystal Biotech, Inc. | Rose 14.6% over 21 sessions and closed at the assessment-period high. Q2 VYJUVEK revenue reached $119.2 million, while 94.6% gross margin, strong profitability, international launches, and second-half 2026 clinical readouts support continuation. | Closed | -7.0% |
| Nov 3 | Nov 10 | KRYS | Krystal Biotech, Inc. | Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build. | Closed | +0.9% |